An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54) - Gray, A.; Clarke, P.; Raikou, M.; Adler, A.; Stevens, R.; Neil, A.; Cull, C.; Stratton, I.; Holman, R. (Diabetic medicine, 2001)
Keywords: Adrenergic beta-Antagonists - economics; Adrenergic beta-Antagonists - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - economics; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Associated diseases and complications; atenolol; Atenolol - economics; Atenolol - therapeutic use; Biological and medical sciences; captopril; Captopril - economics; Captopril - therapeutic use; Confidence Intervals; cost; Cost-Benefit Analysis; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - economics; Diabetes Mellitus, Type 2 - physiopathology; Diabetes. Impaired glucose tolerance; economic evaluation; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Family Practice - economics; Follow-Up Studies; Glycated Hemoglobin A - analysis; Hospitalization - economics; Humans; hypertension; Hypertension - complications; Hypertension - drug therapy; Hypertension - economics; Hypoglycemic Agents - economics; Hypoglycemic Agents - therapeutic use; Medical sciences; Time Factors; Treatment Outcome; Type 2 diabetes; United Kingdom; United Kingdom; Europe; Endocrinopathy; Human; Hypertension; Captopril; Cardiovascular disease; Atenolol; Non insulin dependent diabetes; Chemotherapy; Treatment; Antihypertensive agent; Blood pressure; Comparative study; Cost efficiency analysis